Tagged with GE

strategy Long-term strategy is the name of the game for Janssen. Alejandro Smolje, the company’s director of finance for Latin America South, outlines how that strategy is implemented in Argentina and highlights the affiliate’s emphasis on its clinical research and its impact on Argentina’s healthcare environment.   What have been some…

clinical trials The Mexico country manager of the Swiss biopharmaceutical company discusses the recent restructuring process the subsidiary has been going through, the strategic importance of Mexico as a logistic and clinical research hub for the region as well as how the company is going digital.     In the past ten…

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

pain management Mundipharma Malaysia’s country manager discusses his company’s aim to become a reference in Malaysia for pain management, on the back of the tremendous 48 percent growth of the business last year.    Mundipharma has recently entered a booming Malaysian pharmaceutical sector. What are your first impressions of the Malaysian market? Malaysia’s pharmaceutical sector…

Aspen Aspen Malaysia’s country manager details the company’s success in the country with a specific business model based on acquiring and remarketing originators. Although Aspen is a renowned generic player, market dynamics have pushed the company in a different direction until today in Malaysia.     Malaysia only became one of Aspen’s…

Sandoz The general manager of Sandoz South Latam weighs up the factors that have allowed his company to be the leader in biosimilars and differentiated generics.     Could you please give us a broad overview of the generics market in Argentina over the last decade? The dynamics of the generic…

similars The vice president of Laboratorios Beta discusses the factors of why his organization is on the  way to consolidating its different business lines and becoming a pure pharmaceutical company.     2014 marks the 74th anniversary of Laboratorios Beta. To what extent is the company today still the same company…

generics Chile is aiming to achieve complete bioequivalence of generics by the end of 2014. Chile’s Public Health Institute is leading the bioequivalence testing, aimed at regulating differences between generic and bioequivalent drugs. The recently appointed director of the Public Health Institute, Ricardo Fabrega, echoes the need for drastic change and…

OTC The general manager of Gennoma Laboratorios Argentina weighs up the factors of why raising brand awareness using public television is the key success to his company communication strategy.   When did Genomma first arrive in Argentina, and what is your strategy in the country today? Genomma Laboratories Argentina started in…

amgen Roland Wandeler, general manager of Amgen Iberia, discusses the affiliate’s commitment to innovation, clinical trials, and the importance of providing both medicines and solutions in order to foster a more sustainable health ecosystem for the future of Spain. You became general manager of Amgen Iberia in 2012, in the middle…